Suppr超能文献

铁螯合疗法

Iron Chelation Therapy.

作者信息

Cappellini Maria Domenica, Scaramellini Natalia, Leoni Simona, Motta Irene

机构信息

SC Medicina ad Indirizzo Metabolico, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy.

Dipartimento di Scienze Cliniche e di Comunità, Dipartimento di Eccellenza 2023-2027, University of Milan, Milan, Italy.

出版信息

Adv Exp Med Biol. 2025;1480:361-370. doi: 10.1007/978-3-031-92033-2_23.

Abstract

Iron overload is a serious complication associated with transfusion-dependent anemias and anemias characterized by ineffective erythropoiesis. Iron accumulation is toxic to many tissues, causing heart failure, cirrhosis, liver cancer, growth retardation, and multiple endocrine abnormalities.Chelation therapy aims to balance the rate of iron accumulation from blood transfusions by increasing iron excretion in urine and/or feces with chelators. Three iron chelators are currently available to treat patients: one administered parenterally called deferoxamine (or desferrioxamine) and two oral chelators, deferiprone and deferasirox. Careful dose adjustment is necessary to avoid excess chelation as iron levels fall.A key factor for successful iron chelation is to achieve regular adherence to treatment regimens throughout life: while the convenience and tolerability of individual chelators are important in achieving this goal, other factors such as psychological well-being and family and institutional support also impact adherence and outcomes.

摘要

铁过载是一种与依赖输血的贫血症以及以无效红细胞生成特征的贫血症相关的严重并发症。铁蓄积对许多组织有毒性,会导致心力衰竭、肝硬化、肝癌、生长发育迟缓以及多种内分泌异常。螯合疗法旨在通过使用螯合剂增加尿液和/或粪便中的铁排泄量,以平衡输血导致的铁蓄积速率。目前有三种铁螯合剂可用于治疗患者:一种通过肠胃外给药的去铁胺(或去铁草酰胺),以及两种口服螯合剂,去铁酮和地拉罗司。随着铁水平下降,必须谨慎调整剂量以避免过度螯合。成功进行铁螯合的一个关键因素是在一生中始终定期坚持治疗方案:虽然个别螯合剂的便利性和耐受性对于实现这一目标很重要,但其他因素,如心理健康以及家庭和机构支持,也会影响依从性和治疗效果。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验